Novo Nordisk presents Tresiba data showing significantly lower hypoglycaemia rates
pharmafile | June 13, 2016 | News story | Research and Development, Sales and Marketing | Novo Nordisk, Tresiba
Novo Nordisk (CPH: NOVO-B) has presented new Phase IIIb data on Tresiba (insulin degludec) at the American Diabetes Association annual meeting which shows significantly lower rates of several types of hypoglycaemia in type-1 and type-2 patients, compared to those treated with insulin glargine U100.
Hypoglycaemia episodes, which range from mild to severe and can greatly impact quality of life, occur in type-1 patients an average of twice a week, while those with type-2 diabetes experience them once a fortnight.
For type-1 patients in the late stage SWITCH trials, which were the first ever double-blinded, crossover basal insulin studies, patients on Tresiba experienced significantly lower rates of severe or blood-glucose confirmed symptomatic hypoglycaemia versus insulin glargine U100. Patients also enjoyed significantly reduced rates of severe hypoglycaemia and confirmed symptomatic nocturnal hypoglycaemia.
In type-2 patients, Tresiba also showed significantly lower rates of severe hypoglycaemia and, in both sets of patients, HbA1c non-inferiority of Tresiba versus insulin glargine U100.
Dr Simon Heller, professor of clinical diabetes at Sheffield University, says: “Hypoglycaemia is a common concern for patients I see treated with insulin, particularly night-time episodes that are harder to detect and manage. The SWITCH results add important new evidence to the overall body of data supporting the use of insulin degludec for patients living with type-1 or type-2 diabetes who experience problematic hypoglycaemia – and provide additional clinical approaches in this important group of patients.”
Sean Murray
Related Content
FDA approves Wegovy for treatment of MASH in adults with liver fibrosis
The US Food and Drug Administration (FDA) has granted accelerated approval for Wegovy (semaglutide) as …
BioMed X and Novo Nordisk partner on oral peptide drug delivery innovation
BioMed X has announced a new collaboration with Novo Nordisk to improve oral delivery of …
Pila Pharma raises SEK 20m to advance new oral obesity treatment
Swedish biotech, Pila Pharma, has raised nearly SEK 20m, equivalent to €1.7m in a capital …
